Who we are
We are a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on our proprietary technological platform DOS47.
DOS47 is our patented oncology platform technology that offers a new and revolutionary approach to the debilitation and destruction of cancer cells by modulating the tumor microenvironment.learn more
Patented oncology platform technology to destroy cancer cells
Designed to induce an increase in pH locally at the site of cancerous cells
Combat tumor acidity and restore immunity